Compound ID | 1736
Synonym(s): ETI-204
Class: Antibody (monoclonal antibody [mAb])
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against B. anthracis |
| Description: | Combination treatment for Inhalational anthrax caused by Bacillus anthracis |
| Institute where first reported: | Elusys Therapeutics Inc |
| Year first mentioned: | 2005 |
| Highest developmental phase: | Approved by FDA in 2016 |
| Development status: | Approved |
| External links: | |
| Guide to Pharmacology: | obiltoxaximab |
| Citations: |
|